Avacta Group Plc (AIM:AVCT)

Market Cap	148.18M
Revenue (ttm)	22.62M
Net Income (ttm)	-25.89M
Shares Out	389.96M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,942,368
Average Volume	1,845,629
Open	39.77
Previous Close	37.50
Day's Range	37.00 - 42.00
52-Week Range	26.00 - 86.40
Beta	-0.16
RSI	61.95
Earnings Date	May 29, 2025

About Avacta Group

Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets. The company develops AVA6000, a peptide drug conjugate form of doxorubicin that is in Phase I clinical trial to treat local...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 154
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: AVCT

Financial Performance

In 2023, Avacta Group's revenue was 23.25 million, an increase of 140.83% compared to the previous year's 9.65 million. Losses were -24.95 million, -31.90% less than in 2022.